Boston Scientific reported third-quarter sales growth of 1.5% and projected a fourth-quarter decline, while also issuing full-year targets for sales growth and adjusted earnings per share in 2026.
The medical-device maker recorded $5.138 billion in sales for the quarter. Sales rose 1.5% year over year under each of the company’s reported, operational and organic measures. Net income attributable to Boston Scientific common stockholders was $582 million, down from $755 million a year earlier. Earnings per share under generally accepted accounting principles were 40 cents, compared with 51 cents; adjusted earnings per share were 73 cents, versus 75 cents.
Boston Scientific estimated that fourth-quarter sales would fall about 1% to 3% on both a reported and organic basis. It forecast adjusted earnings per share of 77 cents to 79 cents for the quarter. For 2026, the company projected reported sales growth of about 4.25%, organic growth of about 3.75% and adjusted earnings per share of $3.16 to $3.18.
Regional operational sales rose 6.1% in Europe, the Middle East and Africa and 10.5% in Latin America and Canada. In Asia-Pacific, operational sales declined 1.1%, while reported sales fell 0.6%. U.S. sales increased 0.5% on both reported and operational bases. The company’s operational measure excludes foreign-exchange effects.
Chairman and CEO Mike Mahoney praised the global teams’ response to the cybersecurity incident and said recovery work and customer and patient support were continuing.
Boston Scientific disclosed the results in an earnings release attached to a Form 8-K filed with the U.S. Securities and Exchange Commission on Oct. 28. The SEC filing index lists disclosures covering results of operations and financial condition, as well as financial statements and exhibits. The company scheduled an analyst call for 8 a.m. ET Wednesday.
